Compound overview
Semaglutide: a GLP-1 receptor agonist research overview
Semaglutide is a synthetic long-acting analogue of glucagon-like peptide-1 (GLP-1) and a selective agonist at the GLP-1 receptor. It is one of the most widely referenced single-receptor incretin peptides in metabolic and endocrine research.
Structure and half-life
A fatty-acid (acylation) modification promotes binding to albumin, which extends the half-life to roughly one week. This long duration underlies the once-weekly protocols used across much of the reference literature.
Research context
Semaglutide is studied as a selective GLP-1 receptor agonist across metabolic and endocrine research models, and often serves as a single-receptor reference point.
Comparative incretin research
It is frequently examined alongside the dual GIP/GLP-1 agonist tirzepatide and the triple GLP-1/GIP/glucagon agonist retatrutide.
This overview is provided for educational and laboratory-research purposes only. It summarises published research and proposed mechanisms; it is not medical advice and does not describe or recommend human or veterinary use. Products are supplied strictly for laboratory research use only — not for human or veterinary consumption, and not a drug, food or cosmetic.